<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335719">
  <stage>Registered</stage>
  <submitdate>14/07/2010</submitdate>
  <approvaldate>29/07/2010</approvaldate>
  <actrnumber>ACTRN12610000621011</actrnumber>
  <trial_identification>
    <studytitle>Effect of silymarin in prevention of adverse effects of anti tuberculosis drugs.</studytitle>
    <scientifictitle>Evaluation of Silymarin in prevention of anti tuberculosis drug induced hepatitis in patients newly diagnosed with tuberculosis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>"Nil"</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Tuberculosis</healthcondition>
    <healthcondition>Drug induced hepatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Silymarin 420 mg per day, for the first 2 weeks of anti-tuberculosis treatment, as oral tablets</interventions>
    <comparator>Placebo, Lactose 420 mg per day, for the first 2 weeks of anti-tuberculosis treatment, as oral tablets</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of drug induced hepatitis, 
Drug induced hepatitis means 3 times elevation of liver enzymes with clinical symptoms or 5 times without symptoms. / measurement of liver enzymes</outcome>
      <timepoint>First two weeks of treatment initiation trice per week  day 2, 4, 6, 9, 11, 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of silymarin adverse effects i. e. nausea, vomiting, bloating, diarrhea, itching by patient questionnaires and daily checklist.</outcome>
      <timepoint>Continuously first two weeks of treatment initiation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>New cases of tuberculosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Infection with Human Immune deficiency virus 
2. Infection  with hepatitis B virus 
3. Infection  with hepatitis c virus 
4. Abnormal liver function tests in the base
5. Patients treated with the regimens other than Isoniazide, Rifampin, Pyrazinamide.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2010</anticipatedstartdate>
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/11/2010</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>72</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>5/02/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Tuberculosis and Lung Disease (NRITLD)</primarysponsorname>
    <primarysponsoraddress>Dar Abad street, Niavaran, Tehran, post code: 1955841452</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti medical university</fundingname>
      <fundingaddress>Velenjak street, Evin, Tehran, post code: 1955841452</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Masih Daneshvari Hospital</sponsorname>
      <sponsoraddress>Dar Abad street, Niavaran, Tehran, post code: 1955841452</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>One of most important adverse effects of anti tuberculosis drugs is drug induced hepatitis. Adverse effects of drugs are one of causes for treatment interruption. Purpose of this study is prevention or decreasing incidence of drug induced hepatitis.</summary>
    <trialwebsite />
    <publication>Iran J Pharm Res. 2016 Winter;15(1):247-52.
Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial.
Marjani M1, Baghaei P1, Kazempour Dizaji M2, Gorji Bayani P1, Fahimi F3, Tabarsi P1, Velayati AA2.
Author information
Abstract

Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment. 

Full text of article is available in: http://ijpr.sbmu.ac.ir/article_1825.html</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NRITLD reseaarch ethihs committee</ethicname>
      <ethicaddress>NRITLD, Dar Abad, Niavaran, Tehran.</ethicaddress>
      <ethicapprovaldate>14/07/2009</ethicapprovaldate>
      <hrec>p/25/29/50438</hrec>
      <ethicsubmitdate>13/07/2009</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Majid marjani</name>
      <address>National Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Dar Abad street, Niavaran, Tehran, post code:1955841452</address>
      <phone>+982126109590</phone>
      <fax>+982126109590</fax>
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Majid Marjani</name>
      <address>National Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Dar Abad street, Niavaran, Tehran, post code:1955841452</address>
      <phone>+982126109590</phone>
      <fax>+982126109590</fax>
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Majid Marjani</name>
      <address>Masih Daneshvari Hospital,Dar Abad, Niavaran, Tehran, Postal code: 19569-44413
</address>
      <phone>+982126109590</phone>
      <fax />
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>